Retatrutide 60mg Pen

Retatrutide 60mg Pen is a triple receptor agonist developed by Eli Lilly and studied for its effects on metabolism, appetite signalling, and body weight regulation. Unlike earlier compounds that focus on a single pathway, Retatrutide targets GLP-1, GIP, and glucagon receptors together.

This multi-pathway approach has made it one of the most discussed compounds in current metabolic research, particularly in studies linked to weight management and blood glucose regulation. Researchers are especially interested in how these hormone pathways may work together to influence appetite, energy expenditure, and long-term metabolic response.